1.16881
Fractogel® EMD TMAE (M)
Synonym(s):
Biochromatography, Fractogel® Ion exchangers, Ion exchanger for LC (Fractogel® TSK/EMD), Fractogel® EMD TMAE (M)
About This Item
Recommended Products
ligand
(Trimethylammoniumethyl)
Quality Level
description
strong anion exchanger, suspension in 20% ethanol and 150 mM NaCl (40-90 µm)
sterility
sterile (Caustic Stable)
product line
Fractogel®
form
resin
parameter
240 cm/hr flow rate
8 bar max. pressure
matrix active group
methacrylate
mean particle size
40-90 μm
capacity
100 mg binding capacity (BSA/mg of resin)
transition temp
flash point 35 °C (calculated)
density
1.430 g/cm3 at 20 °C
bulk density
1000 kg/m3
application(s)
gene therapy
mAb
recombinant protein
separation technique
anion exchange
strong anion exchange
storage temp.
no temp limit
Looking for similar products? Visit Product Comparison Guide
General description
Features and Benefits
- High protein loading conditions resulting in good selectivity and resolution with the tentacle technology
- Excellent binding to large viruses at increased loading
- Homogenous binding with high selectivity and purity
- Reduce operating costs and resin replacement with enduring durability - allowing for multiple cycles of column regeneration and sanitization
- Compatibility with 2.5 % (v/v) aqueous benzyl alcohol containing 150 mM NaCl storage solution
Packaging
- 1.16881.0100: Fractogel® EMD TMAE (M) Resin 100ml
- 1.16881.0010: Fractogel® EMD TMAE (M) Resin 10ml
- 1.16881.0500: Fractogel® EMD TMAE (M) Resin 500ml
- 1.16881.0050: Fractogel® EMD TMAE (M) Resin 50ml
Analysis Note
Microscopic evaluation: Uniform spherical particles,no agglomerates,no fines
Extractable matter (water): ≤ 0.03 %
Cerium: ≤ 1 µg/g
Pressure drop(column: ID=1.6 cm, L=10 cm at 5 ml/min): ≤ 1.0 bar
Particle size (d10): 37 - 45 µm
Particle size (d50): 48 - 60 µm
Particle size (d90): 63 - 77 µm
Colony forming units (TAMC + TYMC): ≤ 100 CFU/ml
Endotoxins: ≤ 1.00 EU/ml
Protein binding capacity (bovine serum albumin): 80 - 120 mg/ml
Functional test (b:a): ≤ 0.25
Functional test: Separation of conalbumin and human serum albumin
Legal Information
Not finding the right product?
Try our Product Selector Tool.
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Flam. Liq. 3
Storage Class Code
3 - Flammable liquids
WGK
WGK 1
Flash Point(F)
95.0 °F
Flash Point(C)
35 °C
Regulatory Listings
Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.
FSL
Group 4: Flammable liquids
Type 2 petroleums
Hazardous rank III
Water insoluble liquid
ISHL Indicated Name
Substances Subject to be Indicated Names
ISHL Notified Names
Substances Subject to be Notified Names
JAN Code
1168815000:
1168810100:
1168815003:
1168810013:
1.16881.5001:
1168810103:
1168819999:
1168810500:
1.16881.0025:
1168810000:
1168810010:
1168810503:
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Articles
Influenza vaccines are commonly made using egg-based and cell-based manufacturing strategies. Find step-by-step information on the manufacturing process for each method.
A custom-designed cost model is used to explore the economics of vaccine manufacturing across several different modalities including mRNA. The model enables greater process understanding, simulates bottlenecks, and helps to optimize production efficiency.
Learn more one the attenuated viral vaccines manufacturing process: cell culture, clarification, nuclease treatment, chromatography, and sterile filtration.
This technical article breaks down the steps of upstream and downstream bioprocessing and formulation of virus-like particle vaccines.
Related Content
This technical article breaks down the adenovirus vaccine manufacturing process and provides a case study on developing an accelerated and cost-effective single-use adenoviral vector vaccine.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service